menu
    • menu

    Company profile for Ascletis Pharma

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ascletis’ mission：Innovative cures liberate life to the fullest. Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Ascletis’ vision ：To become the most innovative world-class biomedical company. Led by a management team with deep expertise and a proven track record, we have developed an integrated platfor...
    Ascletis’ mission：Innovative cures liberate life to the fullest. Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Ascletis’ vision ：To become the most innovative world-class biomedical company. Led by a management team with deep expertise and a proven track record, we have developed an integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ascletis PharmaChina Flag
    Country
    Country
    China
    Address
    Address
    1785 Jianghai Rd, Bldg No.1, Ste 804, Binjiang District, Hangzhou, Zhejiang
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ascletis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203051/0/en/Sagimet-s-License-Partner-Ascletis-Announced-Acceptance-of-New-Drug-Application-for-Denifanstat-for-the-Treatment-of-Moderate-to-Severe-Acne-by-China-s-National-Medical-Products-Ad.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Ascletis Announces China NMPA Acceptance of NDA for Denifanstat
    Ascletis Announces China NMPA Acceptance of NDA for Denifanstat

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-china-national-medical-products-administration-acceptance-of-new-drug-application-for-denifanstat-asc40-a-first-in-class-fasn-inhibitor-for-acne-treatment-302637708.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    Ascletis reports 7.7% weight loss for oral GLP-1 contender
    Ascletis reports 7.7% weight loss for oral GLP-1 contender

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-oral-small-molecule-glp-1--asc30--demonstrated-placebo-adjusted-weight-loss-of-7-7-with-better-gastrointestinal-tolerability-in-its-13-week-us-phase-ii-study-in-participants-with-obesity-or-overweight-302635182.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Ascletis Selects ASC37: First Oral Triple Agonist
    Ascletis Selects ASC37: First Oral Triple Agonist

    30 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-selects-its-first-oral-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302628537.html

    PR NEWSWIRE
    30 Nov 2025
    Share Share
    Ascletis Unveils Once-Monthly ASC36/ASC35 Coformulation
    Ascletis Unveils Once-Monthly ASC36/ASC35 Coformulation

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-co-formulation-of-asc36-once-monthly-next-generation-amylin-receptor-agonist-and-asc35-once-monthly-next-generation-glp-1rgipr-dual-agonist-for-clinical-development-302613458.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Ascletis Unveils Comprehensive Results Of ASC30 Studies
    Ascletis Unveils Comprehensive Results Of ASC30 Studies

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-presents-full-analysis-of-phase-ib-study-of-asc30-oral-tablet-phase-ib-study-of-asc30-injection-and-preclinical-study-of-combination-of-asc31-and-asc47-at-obesityweek-2025-302603810.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search